Appoints industry-leading outsourced commercial services providers to support potential product launch in late 2017 Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient ...
Dow Jones received a payment from EQS/DGAP to publish this press release. Hardman & Co Research Hardman & Co Research: Diurnal Group (DNL): First commercial revenues 04-Oct-2018 / 17:10 GMT/BST ...
Provides a new treatment option for adult and adolescent patients suffering from CAH in the UK Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results